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The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell
adhesion to extracellular matrices and platelet aggregation caused by
Saos-2 human osteosarcoma cells
H-S Chiang', R-S Yang2 and T-F Huang'
'Pharmacological Institute and 'Department ofOrthopaedics, College ofMedicine, National Taiwan UniversitY, Taipei, Taiwan.
Sumary Saos-2 cells, derived from a primary human osteosarcoma, caused dose-dependent platelet aggrega-
tion in heparinised human platelet-rich plasma. Saos-2 tumour cell-induced platelet aggregation (TCIPA) was
completely inhibited by hirudin but unaffected by apyrase. The cell suspension shortened the plasma
recalcification times of normal, factor VIII-deficient and factor IX-deficient human plasmas in a dose-
dependent manner. However, the cell suspension did not affect the recalcification time of factor VII-deficient
plasma. Moreover, a monoclonal antibody (MAb) against human tissue factor completely abolished TCIPA.
Flow cytometric analysis using anti-integrin MAbs as the primary binding ligands demonstrated that the
integrin receptors cvP3, 1 and ae8B were present on the surface of Saos-2 cells, which might mediate tumour
cell adhesion to extracellular matrix. Rhodostomin, an Arg-Gly-Asp (RGD)-containing snake venom peptide
which antagonises the binding of fibnrnogen to platelet membrane glycoprotein i1b/i11a, prevented Saos-2
TCIPA as well as tumour cell adhesion to vitronectin, fibronectin and collagen type I. Likewise, the synthetic
peptide Gly-Arg-Gly-Asp-Ser (GRGDS) showed a similar effect. On a molar basis, rhodostomin was about
18 000 and 1000 times. respectively, more potent than GRGDS in inhibiting TCIPA and tumour cell
adhesion.
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The formation of a metastatic lesion is the result of a com-
plex series of events called the 'metastatic cascade'. Following
intravasation, circulating tumour cells interact with a variety
of host cells such as effectors of the cellular immune res-
ponses, endothelial cells and platelets. The interaction of
tumour cells and host platelets may promote the metastatic
process (Honn et al., 1992). Indeed, there is evidence that the
incidence of lymph node metastasis caused by ten cell lines,
from rat renal carcinoma, in vivo correlates well with their
ability to induce platelet aggregation in vitro (Pearlstein et al.,
1980).
Platelets may enhance tumour cell adhesion to endothelial
cells and subendothelial surfaces during the haematogenous
metastasis process. The cell-cell or cell-extracellular matrix
(ECM) interactions of both normal and tumour cells have
been proven to be mediated by a variety of plasma memb-
rane receptors including the integrin family (Hynes et al.,
1987). Integrins are transmembrane proteins which link the
ECM with the cell cytoskeleton. Such linkage enables cellular
attachment to substrata and forms focal adhesion plaques in
distinct plasma membrane regions which establish contact
with the matrix (Grunicke, 1990). The interaction of integrins
with adhesion proteins has been shown to be partially
mediated by binding of integrin to Arg-Gly-Asp (RGD), the
short hydrophilic amino acid sequence within adhesion pro-
teins (Pierschbacher and Rouslahti, 1984; Rouslahti and
Pierschbacher, 1987).
Purified components from snake venoms have been widely
studied and found to affect platelet function, including
trigramin-like anti-platelet peptides (Huang et al., 1987a,
1991a,b; Shebuski et al., 1989; Rucinski et al., 1990). Trigra-
min, an RGD-containing peptide purified from venom of the
Trimeresurus gramineus snake, is a specific antagonist of
platelet membrane glycoprotein Ib/Illa (Huang et al., 1987a,
1989). Rhodostomin, another RGD-containing peptide
purified from the venom of the Malayan pit viper Agkist-
rodon rhodostoma, also inhibits platelet aggregation by
antagonism of the Gp Ilb/Illa-fibrinogen interaction
(Huang et al., 1987b, 1990). These peptides all contain the
RGD sequence, are rich in cysteine and bind with high
affinity to the surface of platelets.
The in vitro metastatic characterisation of osteosarcoma is
not yet well understood. In the present study, we examined in
vitro the TCIPA caused by Saos-2 human osteosarcoma cells.
We probed Saos-2 TCIPA with a variety of inhibitors and
monoclonal antibodies in order to characterise fully the
mechanism of this phenomenon. Rhodostomin was found to
inhibit potently both TCIPA and tumour cell adhesion to
ECM (i.e. fibronectin, vitronectin, collagen type I), which is
closely related to the binding characterisation of RGD-
dependent rhodostomin to the integrins expressed on the
Saos-2 cell surface.
Materals and metbods
Materials
Saos-2 human osteosarcoma cells were obtained from ATCC
(American Type Culture Collection) Laboratory. Crude
venom of Agkistrodon rhodostoma (or Calloselasma rhodos-
toma) was purchased from Latoxan (Rosans, France) and
stored at -20°C. Rhodostomin was purified from venom of
A. rhodostoma as previously described (Huang et al., 1989,
1990). GRGDS was purchased from Peninsula Laboratories,
CA, USA. Gly-Arg-Gly-Glu-Ser (GRGES) was synthesised
by the Biochemical Institute, College of Medicine, National
Taiwan University. Apyrase (grade III), heparin, hirudin
(grade IV from leeches), fibronectin (from bovine plasma),
vitronectin (from human plasma), laminin (from basement
membrane of mouse sarcoma), collagen type I (from calf
skin) and type IV were obtained from Sigma (St Louis, MO,
USA). Tissue thromboplastin reagent was Simplastin Excel
standard (Organon Teknika, NC, USA). Coagulation factor-
deficient human plasmas (deficient in factor VII, VIII or IX)
were obtained from Sigma.
Monoclonal antibodies (MAbs) 7E3 and IOE5 raised
against the glycoprotein (GP) Ilb/Illa complex were kindly
supplied by Dr B Coller (State University of New York,
Stony Brook, NY, USA). MAb to human tissue factor was
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obtained from Biogenesis (Bournemouth, UK. MCA757
(anti-a), MCA698 (anti-a1), MCA699 (anti-4a) and
MCA794 (anti-a38) were purchased from Serotec (Bicester,
UK). Goat anti-mouse IgG-FITC was from Boehringer
(Mannheim, Germany). Cell culture reagents and materials,
inuding Dulbecco's modified Eagle medium (DMEM) and
fetal calf serum (FCS) were from Gibco (Grand Island, NY,
USA). FCS was heat inactivated at 56-C for 30min prior to
use.
Cell culture
Saos-2 cells were cultured in a 95% air-5% carbon dioxide
atmosphere using tissue culture-grade plastic flasks. Cells
were grown in DMEM supplemented with 10% FCS, 2 mM
L-glutamine, penicillin (100 U ml-) and streptomycin (100pg
ml-'). Confluent monolayers were harvested from culture
flasks with brief 0.1% trypsin- I mM EDTA treatment They
were washed three times to remove residual FCS and finally
resuspended in phosphate-buffered saline (PBS: 137 mM
sodium chloride, 2.7 mM potassium chloride, 4.3 mM
disodium hydrogen phosphate, 1.4mM potassium phosphate,
pH 7.25). Based on trypan blue exclusion studies, cell
viability was greater than 95%.
Aggregation studies
Human blood was anticoagulated with heparin (final concen-
tration I Uml-'). Platelet-rich plasma (PRP) was prepared
by centrifugation at 120g for Omin at room temperature.
Platelet-poor plasma (PPP) was prepared from the remaining
blood by additional centrifigation at 500g for 10 min PRP
was adjusted with PPP to contain about 3 x 10' platelets/ml.
Platelet aggregation was measured turbidimetrically with a
Lumi-aggregometer (Chrono-log). PRP (400gi) was pre-
warmed at 37C for 2 min in a si ne-treated g cuvette.
Each inhibitor, snake venom, monoclonal antibody or pep-
tide was added at various tmes before addition of 20gl of
.cell suspension (3 x I04 cells ml-', final concentration). The
reaction was allowed to proceed for at least 10 min and the
degree of aggregation expressed as changes in light transmis
sion.
Meaurement ofprocoagulant activity
Procoagulant activity of the cell suspension was measured by
plasma recakification time (Sheu et al., 1992). PPP was
prepared from whole blood, collected from healthy human
volunteers and mixed with 3.8% (w/v) sodium citrate (9:1,
v/v). In brief, 100id of either fresh normal citrated PPP or
human factor-deficient plamas (deficient in factor VII, VIII
or IX) was incubated with 100gi of cell suspension contain-
ing various concentrations of tumour cells for 2 min at 3TC.
Thereafter, 100PI ofprewarmed 25 mM calcium chloride was
added, and the plasma clotting time determined by a fibro-
metry (Coag-a-mate, Organon Teknika, NC, USA). Tisu
thromboplastin was used as a positive control for activating
the extrinsic coagulation pathway.
Fow cytometric analysis
Flow cytometric studies were performed to quantify surface
expression of integrins (Grossi et al., 1989). Cells were
detached (using 0.5 mM EDTA), washed free of serum pro-
teis with Hanks' balanced salt solution (HBSS, pH 7.25)
containing 2 mM Ca2+ and 2 mM Mg2+, then finally suspend-
ed at a concentration of 106 cells per sample. Cells were fixed
with paraformaldehyde (0.07%, 10min) prior to labelling for
surface integrins. The fixed cells were blocked with normal
goat serum (1:2) for 25 min, and labelled with MAbs (25pg ml-') for I h. After washing, cells were finally relabelled with
goat anti-mouse IgG-FITC. FITC signals were detected and
digitised in logarithmic configuration and the data collected
on a EPICS computer system. Data were collected at 256-
channel resolution and 10 000 cells were counted per experi-
mental group. Fluorescence intensity was directly propor-
tional to the fluorescein label present on the tumour cell
surface. The control fluorescence intensity was obtained with
cell suspension in which primary antibodies were omitted. All
experiments were repeated at least four times.
Adhesion studies
2',7'-Bis-(2-carboxyethyl)-5(and-6)-carboxyfluorescein acetoxy-
methyl (BCECF-AM) has been used in fluorescence-based
viability assesent in adherent cell cultures (Vaporciyan et
al., 1993). In our study, cells (5 x 104) were incubated with
fluorescent dye (2jugml-') in HBSS for 30 min at 37C.
Following incubation, cells were washed once in PBS, and
finally reuspended in serum-free DMEM/HF12K containing
0.5% ofthe medium supplement ITS +. Plates (96-well; CoS-
tar, USA) were coated overnight at 4C with 50gil of
fibronectin (30jigml-'), vitronectin (I5#cg ml-'), laminin
(15 lgml-') and collagen type I and type IV (80gigml-') in
PBS. Cells were treated with rhodostomin or GRGDS
(15 min at 25C) before adhesion assay. Control or treated
cells (2.5 x 10w) were added to each well and incubated for
24h at 3TC. The non-adherent cells were removed by aspira-
tion and the plates read with a CytoFluor 2300 fluorescence
plate reader (Millipore, Bedford, MA, USA).
Results
Characterisation ofplatelet aggregation iucedby Saos-2
cells
The Saos-2 cell suspension was a potent inducer of irrever-
sible platelet aggregation in heparinised human PRP (Figure
1). This TCIPA was dose dependent and preceded by a lag
phase. Cells at concentrations of more than 5 x I03cells ml-'
caused aggregation. The tracings of aggregation induced by
at least 5 x 10'cells ml-' were interrupted by delayed fibrin
clot formation (Figure 1), which was also grossly evident.
The lag phase preceding aggregation became progressively
shorter with increasing tumour cell concentrations.
Cell suspension at 3 x 1O'cells ml-' was used for the fol-
lowing platelet aggregation studies. Pretreatment with the
ADP scavenger apyrase (0.5 Uml-', final concentration) in
PRP did not inhibit TCIPA (Figure 2), indicating that ADP
is essentially not involved. However, the lag phase preceding
TCIPA was prolonged. Hirudin (5 U ml-'), a specific throm-
bin inhibitor, completely inhibited the aggregation response
(Figure 2), suggesting that formation of thrombin is required
for Saos-2 TCIPA.
Effect ofSaos-2 cells on theplasma recalcfication tine
As shown in Table I, Saos-2 cell suspension shortened the
one-stage recacification time of normal human citrated PPP
in a concentration-dependent manner. The clotting times of
factor VIII- and factor IX-deficient plasmas were similarly
shortened. However, cell suspension did not shorten the
recacification time of factor VII-deficient plasma. A similar
pattern of results was obtained with control thromboplastin.
These data indicated that the procagulant activity of Saos-2
cells is via activation of factor VII in the extrinsic coagula-
tion pathway, leading to the activation of the common path-
way.
Effect ofrhodostomin andmonoclonal antibodies on Saos-2
TCIPA
The binding of fibrinogen to its specific receptor is mainly
through the peptide sequence RGD in fibrinogen (Plow et al.,
1986). Pretreatment of platelets with rhodostomin, an RGD-
containing snake venom peptide (0.5pg ml-'), complely
inhibited Saos-2 TCIPA. This inhibition was also observed
with synthetic peptide GRGDS (500pgml-'), while GRGES
(I mgml-') had no significant effect. Either snake venomRhodosdomn inbifti TCIPA and tumow cd adhesion
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peptide or GRGDS inhibited TCIPA in a dose-dependent
manner (Figure 3). On a molar basis, rhodostomin (IC,.
0.03pM) is a 18 000-fold more potent than GRGDS (ICO.
0.56mM). Pretreatment with MAb 7E, (25 fig ml-') against
the platelet membrane GP Ilb Illa complex completely
inhibited TCIPA (Figure 2). In addition. complete inhibition
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was obtained after pretreatment of cells with MAb against
human tissue factor at 37°C for 20min.
Integrin expression on Saos-2 cells
Integrins are a superfamily of cell-surface glycoproteins that
mediate cell-cell and cell-ECM interactions. To determine
whether integrins are expressed on the surface of Saos-2 cells,
an indirect immunofluorescence measurement using flow
cytometry was performed by utilising MAbs specific for tAJ
(lIOEc). CXVP3 (MCA757), ,;Pl (MCA698), NJ, (MCA699) and
M0 (MCA794) as the primary antibodies. IOE5 does not
cross-react with the vitronectin (vJ33) or fibronectin (C5pl,)
receptors (Coller et al.. 1983; Grossi et al., 1988), and there-
fore may be used to distinguish between these immuno-
logically related glycoproteins. As shown in Figure 4. Saos-2
cells express various integrin molecules (i.e. v3, x5p, and
acB,) as verified by the increment in relative fluorescence
quantified by flow cytometry. This increment in fluorescence
intensity was more marked with the cells labelled with the
MAbs against aXVP3 and cx&Bl than those cells labelled with
MAb against a^6,. An increase in the number of highly
fluorescent cells within the population was also observed
(from 4.7% to 94.8% and 98.1% for cells labelled with MAb
against aEfi3 or a@, respectively; Figures 4 and 5). However,
Saos-2 cells do not express integrins ma, and a, since no
significant increment in fluorescence intensity was found.
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Figre 1 Effect on platelet aggregation of different concentra-
tions by human osteosarcoma Saos-2 in human heparinised PRP.
The arrow indicates the addition of Saos-2 cells. Cell suspensions
containing increasing cell numbers were added to heparinised
PRP to trigger platelet aggregation.
Effect ofrhodostomin on adhesion ofSaos-2 cells to ECM
The tripeptide sequence RGD is present in a number of
adhesion proteins, including fibronectin, fibrinogen, vitro-
nectin. collagen type I and thrombospondin (Ruoslahti and
Pierschbacher, 1987). Therefore we examined the effect of
rhodostomin on Saos-2 cell adhesion to ECM. As shown in
Figure 6, adhesion of tumour cells to ECM was inhibited by
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Table I Recalcification clotting times of normal and coagulation
factor-deficient plasmain thepresenceofSaos-2cells. Datapresentedas
means± s.e.m. (n = 4-5)
Plasma recalcification times (s)
Normal Factor IX Factor VIII Factor VII
deficient deficient deficient
PBS buffer 168±4 168±4 170±5 169±3
Thromboplastin 17± 1 18± 1 17± 1 35±2
Saos-2 cells
2 x IO cells ml[' 79±2 81± 3 78±4 166±3
2 x I05cellsml-' 60±4 63± 1 62± 3 163±5
6 x105 cells ml-' 43±2 45±3 42±2 167±5
2 x 106cells ml-' 34±2 32±2 36±3 145±5
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Figre 2 Effect of hirudin. apyrase. 7E3 and monoclonal anti-
body raised against human tissue factor (MAb to hTF) on Saos-2
TCIPA. A 400 ;d aliquot of heparinised human PRP was prein-
cubated with saline (control); apyrase (0.5 U ml-'). hirudin
(5 U ml') or 7E3 (25igml-') at 37C for 2min, followed by
addition of 20 IL of Saos-2 cells (3 x 10 cells ml'. arrow) to
induce platelet aggregation- MAb to hTF (20 iLg ml-') was prein-
cubated with Saos-2 cells at 37 C for 20min, then the same
number of treated cells were added to heparinised PRP.
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Fgre 3 Effect of rhodostomin, GRGDS and GRGES on Saos-
2 TCIPA. A 400 IlI aliquot of heparinised PRP was preincubated
with varied concentrations of rhodostomin, GRGDS or GRGES
at 3TC for 2 min, followed by addition of Saos-2 cells (3 x
10' cells ml') to induce platelet aggregation. Data presented as
means ± s.e.m. (n = 6).
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Figure 4 Flov :ome:nc anal>';> o: negrn expression on Sao--' cell'. Sao---' ceII 'uspensons w-ere labelled A-;.h M1Ab; ib
NMCA->- Ic) NfCA69_ or di MNCA699. :hen secondanix labelled "-i:h goa: anti-mouse IgG-FITC Cells ib. c and di ;-hooAed a
significant increa-. n vluore'-ene nten'i:x rela::xe :o control cellIS iai xithou: the pnor addition o0: pnmarx an::bodie'- Ten
thousand cell- w-ere counted per expermen:al group HPCV. h:stogram per cen: coefflcient of vana:,on
rhodostomin in a do'-e-dependent manner. At (._ pNi. rhodo-
stomin inhibited ce11 adhesion to collaen txpe I. xitronectin
and fibronectin b! approximately 90o5. However. even at
higher concentration i. /. pm rhodostomin on1v -'lightlx
inhibited cell adhesion to laminin le'- than 2005. and it had
no inhibitorx effect on cell adhesion to collagen t!pe IV.
Synthetic peptide GRGDS s-howed a s-imilar inhibitorx pat-
tern iFizure 6i. On a molar basis. rhodostomin iW 1000-fCold
more potent than GRGDS in inhibiting Sao--' cell adhesion
to RGD-dependent ECNI.
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Discussion
Numerous Studie' using experimental tumour modelS have
suggzested that host platelets mav act a'- causative agents' in
the formation ot successful meta'tatic foci Honn et a"..
1992'. It has been suggested that these aggregation reactions
are involved in the proces' of blood-borne metasta'si'-
(Jamieson er al.. l98- In prexious report'- Gasic et a1..
1968. Pearlstein e! a!.. 19S4 . an adequate platelet number
w-as necessarv for metastasis s-ince induction of thrombo-
cytopenia was associated x-ith a decrease in the number of
metastatic lesions. Moreoxer. manx anti-platelet agents haxe
potent anti-metastasis effect'- Al-Mondhirx ei al.. l9&4). In
clinical practice. osteosarcoma i' metastasis prone. xwhich i'-
Figure Q5 an: nc:on o: fIou %A :omerx o: :n:egrnn- expre'-
'-on on Sao---' cell-s Immunolabellkne o: ur:ace. mnieennS waSa
ertormed as deScr-bed r. the Ieiend :o F:Eure 4 Labelled cell'-
shoved an :ncrea'e :n mean fluore'-cene :n:ens:t 0 relative to
on:rol anda percentage :ncrea', n :he number ot ell' labelled
-A h N'Ab-S Da:a rre-en nd '-i mean'-'-em r =-4i
the main cause of therapeutic failure. In this studx we
sho%ed that Saos-2 cells. isolated from a primarx osteosar-
coma (Rodan et al.. 198h-. are a potent inducer of human
platelet aggregation. Saos-2 cells- are about 10-fold more
potent than human hepatoma cells (Sheu et al.. 1992, in
causing TCIPA. which also cause' fibrin clot formation at
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e 6 )ose-response relationship of rhodostomin (a) and
GRGDS (b) on Saos-2 cell adhesion to immobihised ECM, i.e.
l5pgml' (0), typeI(@)andtypeIVcollagen8Oagml'-1(A).
Adhesion of Saos-2 cefls to each ECM was prondfor 24 h at
37rC. Inhibition of cell adhesion is shown as a percentage of the
control. Data presented as means ± secm. (n = 5-6).
concentrations higher than 5 x lO'cells ml-'. This event
occurs after aggregation since platelet aggregation requires
less thrombin than does fibrinogen proteolysis in PRP. Addi-
tionally, this TCPIPA is observed in heparinised PRP but not
in citrated PRP, and the lag phase preceding platelet aggre-
gation is markedly prolonged by raising the concentration of
heparin from 1 to 6 units ml' (data not shown), suggesting
that the event is mediated by thrombin formation. Further-
more, the shortening of recakcification time in factor VH1I-
and factor IX-deficient pLasmas but not in factor VHI-
deficient plasma and the complete inhibition of TCIPA by
MAb against huiman tissue factor confirm that the pro-
coagulant activity of Saos-2 cells is via the expression of
tissue factor.
Our results indicate that Saos-2 TCIPA is thrombin depen-
dent and that ADP is not fundamentally involved. During
the lag period of platelet aggregation, the accumulation of
thrombin sufficient to trigger aggregation was required. This
is consistent with the observation reported elsewhere that
thrombin inhibitors prolong the lag period in a dose-depen-
dent manner, but do not influence the maximum response of
aggregation once platelets begin to aggregate (Pearistein et
al., 1981). Although Saos-2 TCIPA was essentially thrombin
dependent, apyrase was found to prolong the lag phase
preceding TCIPA. This is also observed with other human
colon adenocarcinoma lines, colo 205 and colo 397 (Scarlett
et al., 1987). The reason may reside in the rate or amount of
thrombin generation. Low concentrations of thrombin are
thought to mediate platelet aggregation in part by triggering
platelet release of ADP, whereas higher concentrations of
thrombin will produce aggregation independent of ADP
release (Kinlough-Rathbone et al., 1977).
Integrin-mediated cell adhesion has been demonstrated for
several RGD-containing proteins found in the mineral com-
partment of bone (Weiss and Reddi, 1980; Oldberg et al.,
1986; Gehron et al., 1989). RGD also appears to be the
active epitope in most disintegrins (Gould et al., 1990). In
this study, we detected various integrins (i.e. vP3, 5l and
aJl) expressed on Saos-2 cels by flow cytometric analysis.
Saos-2 cells do not express integrin ac3, unlike human
colon adenocarcinoma cells (SW-480) and prostate adenocar-
cinoma cells (PC-3) (data not shown). We showed that
rhodostomin inhibits adhesion of Saos-2 cells to several
ECM (i.e., fibronectin, vitronectin and collagen type I), prob-
ably by interfering with several epitopes of the RGD-
dependent integrin receptors. The synthetic peptide GRGDS
has a similar inhibitory effect on adhesion to these ECM,
further confirming that the tripeptide sequence Arg-Gly-Asp
is important for receptor recognition. In the study ofTCIPA,
both rhodostomin and GRGDS and the MAb raised against
GP Hb/HIIa had an inhibitory effect through blockade of
fibrinogen binding to its platelet surface receptor.
A growing body ofevidence strongly suggests that platelets
are indispensable in enabling metastasis. In this study, we
showed that Saos-2 human osteosarcoma cells act as a potent
inducer of platelet aggregation and that thrombin-dependent
TCIPA resulting from tissue factor (TE) activity e on
and tumour cell adhesion to several ECM is inhibitable by
RGD-containing peptides, particuarly the stikingly potent
venom peptide rhodostomin. Therfore, multiple possible
avenues exist for biological and pharmaceutical intervention
in the mana t of neoplastic disease. Because TCIPA
and the adhesion process are seemingly critical steps in
tumour metastass, anti-TF compounds, proteinase inhibitors
and integrin receptor antagonists such as rhodostomin might
have utility as adjunct therapeutic agents in preventing
cancer metastases. Such novel interventions might be relevant
in bone cancer, as suggested in our in vitro studies of
osteosarcoma cells.
TCIPA, tumour cell-induced platelet aggregation; MAb, monoconal
antibody-, RGD, Arg-Gly-Asp; ECM, extracellular matrx; PRP,
platelet-rich plasma; FITC, fluorescein isothiocyanate; TF, tissue
factor.
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